



Kilpeläinen, T. O., Carli, J. F. M., Skowronski, A. A., Sun, Q., Kriebel, J., Feitosa, M. F., Hedman, Å. K., Drong, A. W., Hayes, J. E., Zhao, J., Pers, T. H., Schick, U., Grarup, N., Kutalik, Z., Trompet, S., Mangino, M., Kristiansson, K., Beekman, M., Lyytikäinen, L-P., ... Loos, R. J. F. (2016). Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels. *Nature Communications*, 7, [10494]. <https://doi.org/10.1038/ncomms10494>

Peer reviewed version

Link to published version (if available):  
[10.1038/ncomms10494](https://doi.org/10.1038/ncomms10494)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

# Genome-Wide Meta-Analysis Uncovers Novel Loci Influencing Circulating Leptin Levels

Tuomas O Kilpeläinen<sup>1,2,3</sup>, Jayne F Martin Carli<sup>4</sup>, Alicja A Skowronski<sup>5</sup>, Qi Sun<sup>6,7</sup>, Jennifer Kriebel<sup>8,9,10</sup>, Mary F Feitosa<sup>11</sup>, Åsa K Hedman<sup>12,13,14</sup>, Alexander W Drong<sup>14</sup>, James E Hayes<sup>15,16</sup>, Jinghua Zhao<sup>2</sup>, Tune H Pers<sup>17,18,19</sup>, Ursula Schick<sup>3</sup>, Niels Grarup<sup>1</sup>, Zoltán Kutalik<sup>20,21</sup>, Stella Trompet<sup>22,23</sup>, Massimo Mangino<sup>24,25</sup>, Kati Kristiansson<sup>26,27</sup>, Marian Beekman<sup>28</sup>, Leo-Pekka Lyytikäinen<sup>29,30</sup>, Joel Eriksson<sup>31</sup>, Peter Henneman<sup>32</sup>, Jari Lahti<sup>33,34</sup>, Toshiko Tanaka<sup>35</sup>, Jian'an Luan<sup>2</sup>, Fabiola del Greco M<sup>36</sup>, Dorota Pasko<sup>37</sup>, Frida Renström<sup>38,39</sup>, Sara Willems<sup>40</sup>, Anubha Mahajan<sup>14</sup>, Lynda M Rose<sup>41</sup>, Xiuqing Guo<sup>42</sup>, Yongmei Liu<sup>43</sup>, Marcus E Kleber<sup>44</sup>, Louis Pérusse<sup>45,46</sup>, Tom Gaunt<sup>47</sup>, Tarunveer S Ahluwalia<sup>1,48,49,50</sup>, Yun Ju Sung<sup>51</sup>, Yolande Ramos<sup>52</sup>, Najaf Amin<sup>53</sup>, Antoinette Amuzu<sup>54</sup>, Inês Barroso<sup>55,56,57</sup>, Claire Bellis<sup>58</sup>, John Blangero<sup>58</sup>, Brendan M Buckley<sup>59</sup>, Stefan Böhringer<sup>28</sup>, Der I Chen<sup>42</sup>, Anton JN de Craen<sup>23</sup>, David R Crosslin<sup>60,61</sup>, Caroline E Dale<sup>54</sup>, Zari Dastani<sup>62</sup>, Felix R Day<sup>2</sup>, Joris Deelen<sup>28</sup>, Graciela E Delgado<sup>44</sup>, Ayse Demirkan<sup>53,32</sup>, Francis M Finucane<sup>2</sup>, Ian Ford<sup>63</sup>, Melissa E Garcia<sup>64</sup>, Christian Gieger<sup>8,65,9</sup>, Stefan Gustafsson<sup>12,13</sup>, Göran Hallmans<sup>39</sup>, Susan E Hankinson<sup>66,67</sup>, Aki S Havulinna<sup>26</sup>, Christian Herder<sup>68,69</sup>, Dena Hernandez<sup>70</sup>, Andrew A Hicks<sup>36</sup>, David J Hunter<sup>71</sup>, Thomas Illig<sup>8,72,73</sup>, Erik Ingelsson<sup>12,13,14</sup>, Andreea Ioan-Facsinay<sup>74</sup>, John-Olov Jansson<sup>75</sup>, Nancy S Jenny<sup>76</sup>, Marit E Jørgensen<sup>50</sup>, Torben Jørgensen<sup>77,78,79</sup>, Magnus Karlsson<sup>80</sup>, Wolfgang Koenig<sup>81,82,83</sup>, Peter Kraft<sup>84</sup>, Joanneke Kwekkeboom<sup>74</sup>, Tiina Laatikainen<sup>26,85,86</sup>, Karl-Heinz Ladwig<sup>9,87</sup>, Charles A LeDuc<sup>88</sup>, Gordon Lowe<sup>89</sup>, Yingchang Lu<sup>3</sup>, Pedro Marques-Vidal<sup>90</sup>, Christa Meisinger<sup>9,10</sup>, Cristina Menni<sup>24</sup>, Andrew P Morris<sup>14,91</sup>, Richard H Myers<sup>92</sup>, Satu Männistö<sup>26</sup>, Mike A Nalls<sup>70</sup>, Lavinia Paternoster<sup>47</sup>, Annette Peters<sup>9,10,93</sup>, Aruna D Pradhan<sup>94,41</sup>, Tuomo Rankinen<sup>95</sup>, Laura J Rasmussen-Torvik<sup>96</sup>, Wolfgang Rathmann<sup>97</sup>, Treva Rice<sup>98,51</sup>, J Brent Richards<sup>99,24</sup>, Paul M Ridker<sup>94,41</sup>, Naveed Sattar<sup>100</sup>, David B Savage<sup>57</sup>, Stefan Söderberg<sup>101</sup>, Nicholas J Timpson<sup>47</sup>, Liesbeth Vandenput<sup>31</sup>, Diana van Heemst<sup>23</sup>, Hae-Won Uh<sup>28</sup>, Marie-Claude Vohl<sup>46,102</sup>, Mark Walker<sup>103</sup>, Heinz-Erich Wichmann<sup>104,105</sup>, Elisabeth Widén<sup>27</sup>, Andrew R Wood<sup>37</sup>, Jie Yao<sup>42</sup>, Tanja Zeller<sup>106,107</sup>, Yiyang Zhang<sup>88</sup>, Ingrid Meulenbelt<sup>52</sup>, Margreet Kloppenburg<sup>74,108</sup>, Arne Astrup<sup>109</sup>, Thorkild IA Sørensen<sup>1,110,47</sup>, Mark A Sarzynski<sup>95</sup>, DC Rao<sup>51,98,11</sup>, Pekka Jousilahti<sup>26</sup>, Erkki Vartiainen<sup>26</sup>, Albert Hofman<sup>40,111</sup>, Fernando Rivadeneira<sup>40,112,111</sup>, André G Uitterlinden<sup>40,112</sup>, Eero Kajantie<sup>26,113,114</sup>, Clive Osmond<sup>115</sup>, Aarno Palotie<sup>116,27,55</sup>, Johan G Eriksson<sup>26,34,117</sup>, Markku Heliövaara<sup>26</sup>, Paul B Knekt<sup>26</sup>, Seppo Koskinen<sup>26</sup>, Antti Jula<sup>26</sup>, Markus Perola<sup>26,27,118</sup>, Risto K Huupponen<sup>119,120</sup>, Jorma S Viikari<sup>121,122</sup>, Mika Kähönen<sup>123,124</sup>, Terho Lehtimäki<sup>29,30</sup>, Olli T Raitakari<sup>125,126</sup>, Dan Mellström<sup>31</sup>, Mattias Lorentzon<sup>31</sup>, Juan P Casas<sup>54,127</sup>, Stefanie Bandinelli<sup>128</sup>, Winfried März<sup>129,44,130</sup>, Aaron Isaacs<sup>53</sup>, Ko W van Dijk<sup>32</sup>, Cornelia M van Duijn<sup>53,111,131</sup>, Tamara B Harris<sup>64</sup>, Claude Bouchard<sup>95</sup>, Matthew A Allison<sup>132</sup>, Daniel I Chasman<sup>94,41</sup>, Claes Ohlsson<sup>31</sup>, Lars Lind<sup>133</sup>, Robert A Scott<sup>2</sup>, Claudia Langenberg<sup>2</sup>, Nicholas J Wareham<sup>2</sup>, Luigi Ferrucci<sup>35</sup>, Timothy M Frayling<sup>37</sup>, Peter P Pramstaller<sup>36,134,135</sup>, Ingrid B. Borecki<sup>11</sup>, Dawn M Waterworth<sup>136</sup>, Sven Bergmann<sup>137,21</sup>, Gérard Waeber<sup>90</sup>, Peter Vollenweider<sup>90</sup>, Henrik Vestergaard<sup>1,50</sup>, Torben Hansen<sup>1,138</sup>, Oluf Pedersen<sup>1</sup>, Frank B Hu<sup>71</sup>, P Eline Slagboom<sup>52</sup>, Harald Grallert<sup>8,9,10</sup>, Tim D Spector<sup>24</sup>, J Wouter Jukema<sup>22,139,140</sup>, Robert J Klein<sup>16</sup>, Erik E Schadt<sup>16</sup>, Paul W Franks<sup>141,7,38</sup>, Cecilia M Lindgren<sup>14,142,143</sup>, Rudolph L Leibel<sup>88</sup>, Ruth JF Loos<sup>3,144,2</sup>

\* These authors contributed jointly to this manuscript

1. The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2100, Denmark.
2. MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, CB2 0QQ, UK.
3. Genetics of Obesity and Related Metabolic Traits Program, Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
4. Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, 10032, USA.
5. Institute of Human Nutrition, Columbia University, New York, NY, 10032, USA.
6. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
7. Department of Nutrition, Harvard School of Public Health, Boston, MA, 02115, USA.

8. Research Unit of Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, 85764, Germany.
9. Institute of Epidemiology II, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, 85764, Germany.
10. German Center for Diabetes Research (DZD e.V.), partner site Munich, Munich, 85764, Germany.
11. Department of Genetics, Washington University School of Medicine, St. Louis, MO, 63110, USA.
12. Science for Life Laboratory, Uppsala University, Uppsala, 750 85, Sweden.
13. Department of Medical Sciences, Molecular Epidemiology, Uppsala University, Uppsala, 751 85, Sweden.
14. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK.
15. Cell and Developmental Biology Graduate Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, 10021, USA.
16. Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
17. Divisions of Endocrinology and Genetics and Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, MA, 02115, USA.
18. Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA, 2142, USA.
19. Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA.
20. Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, 1011, Switzerland.
21. Swiss Institute of Bioinformatics, Lausanne, 1015, Switzerland.
22. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
23. Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, 2333, The Netherlands.
24. Department of Twin Research and Genetic Epidemiology, King's College London, London, SE1 7EH, UK.
25. National Institute for Health Research Biomedical Research Centre at Guy's and St. Thomas' Foundation Trust, London, SE1 9RT, UK.
26. National Institute for Health and Welfare, Department of Health, Helsinki, FI-00271, Finland.
27. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, FI-00290, Finland.
28. Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
29. Department of Clinical Chemistry, Fimlab Laboratories, Tampere, Finland.
30. Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere, FI-33014, Finland.
31. Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 413 45, Sweden.
32. Department of Human Genetics, Leiden University Medical Center, Leiden, 2333, The Netherlands.
33. Institute of Behavioural Sciences, University of Helsinki, Helsinki, FI-00014, Finland.
34. Folkhälsan Research Center, Helsinki, FI-00290, Finland.
35. Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, 21225, USA.
36. Center for Biomedicine, European Academy Bozen/Bolzano (EURAC) - Affiliated Institute of the University of Lübeck, Bolzano, 39100, Italy.
37. Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, EX4, UK.
38. Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Skåne University Hospital Malmö, Malmö, 205 02, Sweden.
39. Department of Biobank Research, Umeå University, Umeå, 901 87, Sweden.
40. Department of Epidemiology, Erasmus MC, Rotterdam, 3015 GE, The Netherlands.
41. Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
42. Institute for Translational Genomics and Population Sciences, Department of Pediatrics, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, 90502, USA.
43. Center for Human Genetics, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
44. Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, 68167, Germany.
45. Department of Kinesiology, Laval University, Québec, QC, G1V 0A6, Canada.
46. Institute of Nutrition and Functional Foods, Québec, QC, G1V 0A6, Canada.
47. MRC Integrative Epidemiology Unit & School of Social and Community Medicine, University of Bristol, Bristol, BS82BN, UK.
48. Copenhagen Prospective Studies on Asthma in Childhood, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DK-2820, Denmark.

49. Danish Pediatric Asthma Center, Gentofte Hospital, The Capital Region, Copenhagen, DK-2900, Denmark.
50. Steno Diabetes Center, Gentofte, DK-2820, Denmark.
51. Department of Biostatistics, Washington University School of Medicine, St. Louis, MO, 63108, USA.
52. Leiden University Medical Center, Department of Medical Statistics and Bioinformatics, Section of Molecular Epidemiology, Leiden, 2333, The Netherlands.
53. Genetic Epidemiology Unit, Department of Epidemiology, Erasmus MC, Rotterdam, 3015 GE, The Netherlands.
54. London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, London, WC1E 7HT, UK.
55. Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK.
56. NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
57. University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
58. Texas Biomedical Research Institute, San Antonio, TX, 78245, USA.
59. Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland.
60. Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, WA, 98195, USA.
61. Department of Genome Sciences, University of Washington, Seattle, WA, 98195, USA.
62. Department of Human Genetics, McGill University, Montreal, Quebec, H3A 0G4, Canada.
63. Robertson Center for Biostatistics, University of Glasgow, Glasgow, G12 8QQ, UK.
64. Laboratory of Epidemiology and Population Science, National Institute on Aging, Bethesda, MD, 20892, USA.
65. Institute of Genetic Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, 85764, Germany.
66. Department of Epidemiology, School of Public Health and Health Sciences, University of Massachusetts-Amherst, Amherst, MA, 01003, USA.
67. Department of Epidemiology, Harvard School of Public Health, Boston, MA, 02115, USA.
68. Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
69. German Center for Diabetes Research (DZD), partner site Düsseldorf, Düsseldorf, 40225, Germany.
70. Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, 20892, USA.
71. Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, MA, 02115, USA.
72. Hannover Unified Biobank, Hannover Medical School, Hannover, 30625, Germany.
73. Institute for Human Genetics, Hannover Medical School, Hannover, 30625, Germany.
74. Leiden University Medical Center, Department of Rheumatology, Leiden, 2333, The Netherlands.
75. Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 413 45, Sweden.
76. Laboratory for Clinical Biochemistry Research, Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Colchester, VT, 05405, USA.
77. Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, 2600, Denmark.
78. Faculty of Medicine, University of Aalborg, Aalborg, 9100, Denmark.
79. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark.
80. Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences and Orthopaedic Surgery, Lund University, Skåne University Hospital, Malmö, 214 28, Sweden.
81. Department of Internal Medicine II - Cardiology, University of Ulm, Ulm, 89081, Germany.
82. Deutsches Herzzentrum München, Technische Universität München, Munich, 80636, Germany.
83. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, 80539, Germany.
84. Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA, 02115, USA.
85. Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, FI-70211, Finland.
86. Hospital District of North Karelia, Joensuu, FI-80210, Finland.
87. Department of Psychosomatic Medicine and Psychotherapy, Klinikum Rechts der Isar, Technische Universität München, Munich, 81675, Germany.
88. Department of Pediatrics, Division of Molecular Genetics, Columbia University, New York, NY, 10029, USA.
89. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
90. Department of Internal Medicine, Internal Medicine, Lausanne University Hospital, Lausanne, 1011, Switzerland.
91. Department of Biostatistics, University of Liverpool, Liverpool, L69 3GA, UK.

92. Department of Neurology, Boston University School of Medicine, Boston, MA, 02118, USA.
93. German Center for Cardiovascular Research (DZHK e.V.), partner site Munich, Munich, 80539, Germany.
94. Harvard Medical School, Boston, MA, 02115, USA.
95. Human Genomics Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, 70808, USA.
96. Preventive Medicine, Northwestern Feinberg School of Medicine, Chicago, IL, 60611, USA.
97. Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, 40225, Germany.
98. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, 63110, USA.
99. Departments of Medicine, Human Genetics and Epidemiology, McGill University, Montreal, Quebec, H3A 0G4, Canada.
100. BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, Glasgow, G12 8QQ, UK.
101. Department of Public Health and Clinical Medicine, Cardiology and Heart Centre, Umeå University, Umeå, 901 87, Sweden.
102. School of Nutrition, Laval University, Quebec, G1V 0A6, Canada.
103. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
104. Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, and Klinikum Grosshadern, Munich, 80336, Germany.
105. Institute of Epidemiology I, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, 85764, Germany.
106. German Center for Cardiovascular Research (DZHK e.V.), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany.
107. Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, 20246, Germany.
108. Leiden University Medical Center, Department of Clinical Epidemiology, Leiden, 2333, The Netherlands.
109. Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Copenhagen, 1165, Denmark.
110. Institute of Preventive Medicine, Bispebjerg and Frederiksberg Hospitals, The Capital Region, Copenhagen, 2000, Denmark.
111. Netherlands Consortium for Healthy Aging, Leiden University Medical Center, Leiden, 2300 RC, The Netherlands.
112. Department of Internal Medicine, Erasmus MC, Rotterdam, 3015 GE, The Netherlands.
113. Children's Hospital, Helsinki University Central Hospital and University of Helsinki, Helsinki, FI-00014, Finland.
114. Department of Obstetrics and Gynaecology, MRC Oulu, Oulu University Central Hospital and University of Oulu, Oulu, 90220, Finland.
115. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
116. Massachusetts General Hospital, Center for Human Genetic Research, Psychiatric and Neurodevelopmental Genetics Unit, Boston, MA, 02114, USA.
117. Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, FI-00014, Finland.
118. University of Tartu, Estonian Genome Centre, Tartu, 51010, Estonia.
119. Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, FI-20520, Finland.
120. Unit of Clinical Pharmacology, Turku University Hospital, Turku, FI-20520, Finland.
121. Division of Medicine, Turku University Hospital, Turku, FI-20520, Finland.
122. Department of Medicine, University of Turku, Turku, FI-20520, Finland.
123. Department of Clinical Physiology, Tampere University Hospital, Tampere, FI-33521, Finland.
124. Department of Clinical Physiology, University of Tampere School of Medicine, Tampere, FI-33014, Finland.
125. Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, FI-20521, Finland.
126. Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, FI-20520, Finland.
127. Institute of Cardiovascular Science, University College London, London, WC1E 6BT, UK.
128. Geriatric Unit, Azienda Sanitaria Firenze, Florence, 50122, Italy.
129. Synlab Academy, Synlab Services LLC, Mannheim, 70469, Germany.
130. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, 8010, Austria.
131. Center of Medical Systems Biology, Leiden, The Netherlands.
132. Family and Preventive Medicine, University of California San Diego, La Jolla, CA, 92161, USA.
133. Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, 751 85, Sweden.
134. General Central Hospital, Department of Neurology, Bolzano, 39100, Italy
135. Department of Neurology, University of Lübeck, Lübeck, 23562, Germany.

136. GlaxoSmithKline, King of Prussia, PA, 19406, USA.
137. Department of Medical Genetics, University of Lausanne, Lausanne, 1015, Switzerland.
138. Faculty of Health Sciences, University of Southern Denmark, Odense, 5230, Denmark.
139. Interuniversity Cardiology Institute of the Netherlands, Utrecht, 3511 EP, The Netherlands.
140. Durrer Center for Cardiogenetic Research, Amsterdam, 1105 AZ, The Netherlands.
141. Department of Public Health & Clinical Medicine, Umeå University, Umeå, 901 87, Sweden.
142. Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, 02142, USA.
143. The Big Data Institute, University of Oxford, Oxford, OX1 2JD, UK.
144. The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, 10029, New York 10029, USA.

## Short Acknowledgements

Full list of acknowledgements appears in the **Supplementary Information**.

Funding for this study was provided by the Academy of Finland (41071, 117787, 118065, 121584, 124282, 126925, 129494, 129322, 129378, 130326, 134309, 134791, 136895, 139635, 250207, 263836, 286284, 263924); Ahokas Foundation; ALF/LUA research grant in Gothenburg; Amgen; Augustinus Foundation; Becket Foundation; Bristol-Myers Squibb; British Heart Foundation programme (PG/13/66/30442, PG/07/131/24254); Canadian Institutes for Health Research (FRCN-CCT-83028); Centre for Medical Systems Biology; Danish Centre for Health Technology Assessment; Danish Council for Independent Research (DFF-1333-00124, DFF-1331-00730B); Danish Diabetes Association; Danish Heart Foundation; Danish Pharmaceutical Association; Danish Research Council; Department of Health Policy Research Programme (0090049); Diabetes UK; Donald W. Reynolds Foundation; Dutch Arthritis Association (DAA 2010\_017); Dutch government (NWO 184.021.007); Emil Aaltonen Foundation; Erasmus MC; Erasmus University; European Commission (FP6-LSHG-CT-2006-018947, FP6-LSHG-CT-2006-01947, HEALTH-F2-2008-201865-GEFOS, FP7-201668, FP7-223004, FP7-259679, FP7-305739); European Regional Development Fund; EUROSPAN; Faculty of Biology and Medicine of Lausanne; Finnish Centre for Pensions; Finnish Cultural Foundation; Finnish Diabetes Research Society; Finnish Foundation of Cardiovascular Research; Finnish Foundation for Pediatric Research; Finnish National Institute for Health and Welfare; Finnish Special Governmental Subsidy for Health Sciences; Finska Läkaresällskapet; Folkhälsan Research Foundation; Genetic Laboratory of the Department of Internal Medicine, Erasmus MC; German Federal Ministry of Education and Research; GlaxoSmithKline; Göran Gustafsson Foundation; Heart Foundation of Northern Sweden; Helmholtz Zentrum München; Ib Henriksen Foundation; Innovation-Oriented Research Program on Genomics (SenterNovem IGE05007); Italian Ministry of Health (ICS110.1/RF97.71); John W. Barton Sr. Chair in Genetics and Nutrition; Juho Vainio Foundation; King's College London; Knut and Alice Wallenberg Foundation; Kuopio, Tampere and Turku University Hospital Medical Funds (X51001, 9M048, 9N035); Leiden University Medical Centre; Li Ka Shing Foundation; Liv och Hälsa; Local Government Pensions Institution; Ludwig-Maximilians-Universität; Lundberg Foundation; Medical Research Council (MC\_U106179471, MC\_UU\_12013/8); Medical Research Council of Canada; Medical Research Council-GlaxoSmithKline pilot programme grant (G0701863); Ministry of Education, Culture and Science of the Netherlands; Ministry of health, Welfare and Sports of the Netherlands; Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano; Danish Ministry of Internal Affairs and Health; Munich Center of Health Sciences; Municipality of Rotterdam; National

Cancer Institute (CA047988); National Eye Institute; National Institute on Aging (Intramural research program, N01AG62101, N01AG62103, N01AG62106, 1R01AG032098-01A1, 263MD9164, 263 MD 821336); National Institute for Health Research; National Institutes of Health (DK52431, HG004399, HG004446, CA087969, CA055075, DK058845, CA65725, CA49449, CA67262, CA50385, U01CA098233); Netherlands Brain Foundation (HersenStichting Nederland); Netherlands Consortium for Healthy Aging (050-060-810); Netherlands Genomics Initiative; Netherlands Heart Foundation (2001 D 032); Netherlands Organization for Scientific Research (175-010-2005-011, 904-61-095, 911-03-012, 911-03-016, 917-66-344 and 911-03-012); Netherlands Organization for the Health Research and Development; NHLBI (5R01HL068891, 5R01HL087700, R01HL117078, HHSN26800625226C, HHSN268200782096C, HL-043851, HL-045670, HL080467, N01-HC95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, N02-HL-64278, N01-HC-65226, R01-HL-071051, R01-HL-071205, R01-HL-071250, R01-HL-071251, R01-HL-071252, R01-HL-071258, R01-HL-071259, R01-HL-088451, and R00-HL-098459, U01-HG007033, UL1-RR-24156, UL1-RR-25005, UL1-TR-000040, UL1-TR-001079); NHS Foundation Trust; NIDDK (1R01DK080015, R01DK089256, 5R01DK068336, 5R01DK075681, 5R01DK07568102); Novo Nordisk; Novo Nordisk Foundation; New York Obesity Nutrition Research Center Pilot and Feasibility Grant (DK-26687), Orion-Farnos Research Foundation; Pfizer Inc.; Paavo Nurmi Foundation; Pålssons Foundation; Research Foundation of Copenhagen County; Roche Pharmaceuticals; Research Institute for Diseases in the Elderly (014-93-015; RIDE2); Samfundet Folkhälsan; Signe and Ane Gyllenberg Foundation; Sigrid Jusélius Foundation; Social Insurance Institution of Finland; South Tyrolean Sparkasse Foundation; Swedish Diabetes Association; Swedish Diabetes Foundation; Swedish Foundation for Strategic Research; Swedish Heart-Lung Foundation (20140422); Swedish Research Council (2012-1397); Swiss Institute of Bioinformatics; Swiss National Science Foundation (3100AO-116323/1, 33CS0-122661, 33CS30-139468, 33CS30-148401); Tampere Tuberculosis Foundation; Torsten and Ragnar Söderberg's Foundation; Umeå University Career Development Award; Unilever Colworth; Yrjö Jahnsson Foundation; Wellcome Trust (WT064890, WT089062, WT090532, WT098017, WT091551, 081917/Z/07/Z, 086596/Z/08/Z); Wellcome Trust Centre for Human Genetics core funding (090532); Wissenschaftsoffensive TMO.

## Long Acknowledgements

**BLSA:** The BLSA was supported by the Intramural Research Program of the NIH, National Institute on Aging.

**BWHHS:** The British Women Heart and Health Study is supported by British Heart Foundation programme grant no. PG/13/66/30442 and Department of Health Policy Research Programme (0090049). Genotype analysis in BWHHS was supported by the BHF (PG/07/131/24254) and UK Medical Research Council MC\_UU\_12013/8.

**COLAUS:** The CoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (33CSCO-122661, 33CS30-139468 and 33CS30-148401). The authors thank Vincent Mooser and Dawn Waterworth, Co-PIs of the CoLaus study. Special thanks to Murielle Bochud, Yolande Barreau, Mathieu Firmann, Vladimir Mayor, Anne-Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagette, Jeanne Ecoffey and Sylvie Mermoud for data collection. S.B. is grateful for financial support from the Swiss National Science Foundation (Grant #3100AO-116323/1) and the Swiss Institute of Bioinformatics.

**Ely:** We are grateful to all the volunteers and to the staff of St. Mary's Street Surgery, Ely and the study team. The Ely Study was funded by the MRC (MC\_U106179471) and Diabetes UK. Genotyping in the Ely and Fenland studies was supported in part by an MRC-GlaxoSmithKline pilot programme grant (G0701863).

**ERF:** The genotyping for the ERF study was supported by EUROSPAN (European Special Populations Research Network) and the European Commission FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF study was further supported by grants from the Netherlands Organisation for Scientific Research, Erasmus MC, the Centre for Medical Systems Biology (CMSB) and the Netherlands Brain Foundation (HersenStichting Nederland). We are grateful to all participating individuals and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, Jeannette Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection.

**Family Heart Study:** The Family Heart Study is funded by NHLBI grants 5R01HL068891, 5R01HL087700 and R01HL117078, and NIDDK grants 5R01DK068336, 5R01DK075681 and R01DK089256.

**Fenland:** The Fenland Study is funded by the Wellcome Trust and the Medical Research Council (MC\_U106179471). We are grateful to all the volunteers for their time and help, and to the General Practitioners and practice staff for assistance with recruitment. We thank the Fenland Study Investigators, Fenland Study Co-ordination team and the Epidemiology Field, Data and Laboratory teams.

**FINRISK97:** This study has been funded by the Academy of Finland (grant numbers 139635, 129494, 118065, 129322, 250207, 136895, 263836), the Orion-Farmos Research Foundation, the Finnish Foundation for Cardiovascular Research, and the Sigrid Jusélius Foundation. We are grateful for the THL DNA laboratory for its skillful work to produce the DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the samples.



**GARP:** We thank all participants of the GARP study. The Leiden University Medical Centre, the Dutch Arthritis Association and Pfizer Inc., Groton, CT, USA support the GARP study, whilst genotypic work was supported by the Netherlands Organization of Scientific Research (MW 904-61-095, 911-03-016, 917 66344 and 911-03-012), Leiden University Medical Centre, and by the “Centre of Medical Systems Biology” and the “Netherlands Consortium of Healthy Aging” in the framework of the Netherlands Genomics Initiative (NGI). Furthermore, the research leading to these results has received funding from the Dutch Arthritis Association (DAA 2010\_017) and the European Union's Seventh Framework Programme (FP7/2007-2011) under grant agreement n° 259679.

**GEMS:** We acknowledge GEMS Study Investigators: Philip Barter, PhD; Antero Kesäniemi, PhD; Robert W. Mahley, PhD; Ruth McPherson, FRCP; Gerard Waeber MD; and Scott M. Grundy, PhD.

**GLACIER:** We thank the participants, health professionals and data managers involved in the Northern Swedish Health and Disease Study. We specifically thank John Hutiaainen and Åsa Ågren (Umeå Medical Biobank) for data organization, and Kerstin Enquist and Thore Johansson (Västerbottens County Council) for expert technical assistance with DNA preparation. The GLACIER Study was funded by project grants from Novo Nordisk, the Swedish Heart-Lung Foundation, the Swedish Diabetes Association, Pålssons Foundation, the Swedish Research Council, Umeå University Career Development Award, and The Heart Foundation of Northern Sweden (all to P.W.F). F.R. was supported by a post-doctoral stipend from the Swedish Heart-Lung Foundation.

**GOOD:** Financial support was received from the Swedish Research Council, the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg's Foundation, the Novo Nordisk Foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS.

**GOYA:** This study was conducted as part of the activities of the Gene-Diet Interactions in Obesity project (GENDINO, [www.gendinob.dk](http://www.gendinob.dk)) and the MRC centre for Causal Analyses in Translational Epidemiology (MRC CAiTE). We thank all the participants of the study. Tarunveer S. Ahluwalia received his Post Doctoral Fellowship from the GENDINO project and acknowledges the same.

**Health2000:** This study has been funded by the Academy of Finland (grant numbers 129322 and 250207), the Orion-Farmos Research Foundation, the Finnish Foundation for Cardiovascular Research, and the Sigrid Jusélius Foundation. The Health 2000 Study was funded by the National Institute for Health and Welfare (THL), the Finnish Centre for Pensions (ETK), the Social Insurance Institution of Finland (KELA), the Local Government Pensions Institution (KEVA) and other organizations listed on the website of the survey (<http://www.terveys2000.fi>). We are grateful for the THL DNA laboratory for its skillful work to produce the DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the GenMets subcohort.

**HealthABC:** The Health ABC Study was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106 and, in part, by the NIA Intramural Research Program. The genome-wide association study

was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD (<http://biowulf.nih.gov>).

**HBCS:** We thank all study participants as well as everybody involved in the Helsinki Birth Cohort Study. Helsinki Birth Cohort Study has been supported by grants from the Academy of Finland (130326, 134791, 263924), the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Novo Nordisk Foundation, Finska Läkaresällskapet, Signe and Ane Gyllenberg Foundation, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio Foundation, Finnish Foundation for Pediatric Research, Sigrid Juselius Foundation, the Finnish Special Governmental Subsidy for Health Sciences, Samfundet Folkhälsan, Liv och Hälsa, and Wellcome Trust (grant number WT089062). We are grateful for the THL DNA laboratory for its skillful work to produce the DNA samples used in this study. We thank the Sanger Institute genotyping facilities for genotyping the samples.

**HERITAGE:** The HERITAGE Family Study is supported by the National Heart, Lung, and Blood Institute Grant HL-45670

**InCHIANTI:** The InCHIANTI study baseline (1998-2000) was supported as a "targeted project" (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the U.S. National Institute on Aging (Contracts: 263 MD 9164 and 263 MD 821336).

**INTER99:** The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation ([www.metabol.ku.dk](http://www.metabol.ku.dk)). The Inter99 study was initiated by Torben Jørgensen (PI), Knut Borch-Johnsen (co-PI), Hans Ibsen and Troels F. Thomsen. The steering committee comprises the former two and Charlotta Pisinger. The study was financially supported by research grants from the Danish Research Council, the Danish Centre for Health Technology Assessment, Novo Nordisk Inc., Research Foundation of Copenhagen County, Ministry of Internal Affairs and Health, the Danish Heart Foundation, the Danish Pharmaceutical Association, the Augustinus Foundation, the Ib Henriksen Foundation, the Becket Foundation, and the Danish Diabetes Association.

**KORA:** We thank all members of the field staff involved in the KORA study and we express our appreciation to all study participants. We thank the KORA Study Group consisting of A. Peters (speaker), J. Heinrich, R. Holle, R. Leidl, C. Meisinger, K. Strauch, and their co-workers, who are responsible for the design and conduct of the KORA studies. The KORA research platform (KORA, Cooperative Research in the Region of Augsburg) was initiated and financed by the Helmholtz Zentrum München - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ.

**LLS:** The research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2011) under grant agreement number 259679. This study was financially supported by the Innovation-Oriented Research Program on Genomics (SenterNovem IGE05007), the Centre for Medical Systems Biology and the Netherlands Consortium for Healthy Ageing (grant 050-060-810), all in the framework of the Netherlands Genomics Initiative, Netherlands Organization for Scientific Research (NWO), by Unilever Colworth and by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO 184.021.007).

**LURIC:** We extend our appreciation to the participants of the LURIC study; without their collaboration, this article would not have been written. We thank the LURIC study team who were either temporarily or permanently involved in patient recruitment as well as sample and data handling, in addition to the laboratory staff at the Ludwigshafen General Hospital and the Universities of Freiburg and Ulm, Germany. This work was supported by the 7th Framework Program (integrated project AtheroRemo, grant agreement number 201668 and RiskyCAD, grant agreement number 305739) of the European Union and, by the INTERREG IV Oberrhein Program (Project A28, Genetic mechanisms of cardiovascular diseases) with support from the European Regional Development Fund (ERDF) and the Wissenschaftsoffensive TMO.

**MESA:** MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-001079, and UL1-TR-000040. Funding for SHARe genotyping was provided by NHLBI Contract N02-HL-64278. Genotyping was performed at Affymetrix (Santa Clara, California, USA) and the Broad Institute of Harvard and MIT (Boston, Massachusetts, USA) using the Affymetrix Genome-Wide Human SNP Array 6.0. Additional support was provided by R01-HL-088451. Leptin assays were funded by 1R01DK080015.

**MICROS:** For the MICROS study, we thank the primary care practitioners Raffaella Stocker, Stefan Waldner, Toni Pizzocco, Josef Plangger, Ugo Marcadent, and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. The MICROS study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, the South Tyrolean Sparkasse Foundation, and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947).

**MrOS Sweden:** Financial support was received from the Swedish Research Council, the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg's Foundation, the Novo Nordisk Foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS.

**MuTHER:** The MuTHER Study was funded by a program grant from the Wellcome Trust (081917/Z/07/Z) and by core funding from the Wellcome Trust Centre for Human Genetics (090532). Additional funding came from Wellcome Trust and European Community's Seventh Framework Programme (FP7/2007-2013). The study also received support from the National Institute for Health Research (NIHR) Clinical Research

Facility at Guy's & St. Thomas', National Health Service (NHS) Foundation Trust and NIHR Biomedical Research Centre at Guy's and St. Thomas' NHS Foundation Trust and King's College London. Genotyping was performed by the Wellcome Trust Sanger Institute and the National Eye Institute via a National Institutes of Health (NIH) project grant.

**NHS:** This research was supported by NIH grants HG004399, HG004446, CA087969, CA055075, DK058845, CA65725, CA49449, CA67262, CA50385, and UO1CA098233. Qi Sun was supported by a career development award (R00HL098459) from the NHLBI.

**PIVUS:** This research was supported by funding from the Swedish Heart-Lung Foundation (20140422), Knut and Alice Wallenberg Foundation, Swedish Diabetes Foundation (grant no. 2013-024), Swedish Research Council (grant no. 2012-1397), and Göran Gustafsson Foundation. APM is a Wellcome Trust Senior Research Fellow and acknowledges funding from the Wellcome Trust under awards WT098017, WT090532 and WT064890. C.M.L. is a Wellcome Trust Research Career Development Fellow (086596/Z/08/Z) and acknowledges funding from the Li Ka Shing Foundation.

**PROSPER:** The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers Squibb. Prof. Dr. J. W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European commission (grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging grant 050-060-810).

**QFS:** The Quebec Family Study was funded by multiple grants from the Medical Research Council of Canada and the Canadian Institutes for Health Research. This work was supported by a team grant from the Canadian Institutes for Health Research (FRCN-CCT-83028).

**RISC:** DS acknowledges funding from the Wellcome Trust (grant no 091551).

**Rotterdam Study:** The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810.

We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health,

Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.

**TwinsUK:** The study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). The study also receives support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas', NHS Foundation Trust and King's College London. Brent Richards is funded by the CIHR, MDEIE, FRSQ and CFI. SNP Genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute via NIH/CIDR.

**WGHS:** The WGHS is supported by HL043851 and HL080467 from the National Heart, Lung, and Blood Institute and CA047988 from the National Cancer Institute and the Donald W. Reynolds Foundation, with collaborative scientific support and funding for genotyping provided by Amgen. Leptin measures were funded by an investigator-initiated grant from Roche Pharmaceuticals to PMR.

**Young Finns:** The Young Finns Study has been financially supported by the Academy of Finland: grants 286284 (T.L.), 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Kuopio, Tampere and Turku University Hospital Medical Funds (grant X51001 for T.L.); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation of Cardiovascular Research (T.L.); Finnish Cultural Foundation; Tampere Tuberculosis Foundation (T.L.); Emil Aaltonen Foundation (T.L.); and Yrjö Jahnsson Foundation (T.L.). We gratefully acknowledge the THL DNA laboratory for its skillful work to produce the DNA samples used in this study, and Ville Aalto and Irina Lisinen for the expert technical assistance in the statistical analyses.

**Other acknowledgements:** This work was supported in part through the computational resources and staff expertise provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai. Tuomas O. Kilpeläinen is supported by grants no. DFF – 1333-00124 and Sapere Aude DFF – 1331-00730B from the Danish Council for Independent Research. Robert J. Klein was supported by the NHGRI grant U01-HG007033. Data on the childhood obesity trait has been contributed by EGG Consortium and has been downloaded from [www.egg-consortium.org](http://www.egg-consortium.org). Data on glycaemic traits have been contributed by MAGIC investigators and have been downloaded from [www.magicinvestigators.org](http://www.magicinvestigators.org).

## **Competing Interests**

Ines Barroso owns stock in GlaxoSmithKline and Incyte Corporation. Francis M Finucane has received honoraria, speaker fees or research funding from Astra Zeneca, Merck Sharp Dohme, Eli Lilly, Novo Nordisk, and Sanofi. Peter Wollenweider and Gérard Waeber received grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (33CSCO-122661) to conduct the CoLaus study.